The earnings call highlighted significant revenue growth, increased guidance, and strategic investments, indicating strong operational performance and future potential. However, the increase in operating expenses and net loss, primarily due to noncash charges, tempered the overall financial results. The company's strong cash position and strategic investments position it well for future growth, despite near-term financial challenges.

Company Guidance -

Q3 2025

During the BioLife Solutions Q2 2025 conference call, the company reported a strong quarter with a 29% increase in total revenue year-over-year, driven by a 28% increase in cell processing revenue. The adjusted EBITDA margin expanded by 400 basis points to 24%, reflecting the benefits of an optimized product portfolio and streamlined operations. BioLife raised its full-year cell processing revenue guidance to $91 million to $93 million, representing a 24% to 26% growth over the previous year. The company has over $100 million in cash and marketable securities, enabling further investment in strategic priorities. The biopreservation media (BPM) product line accounted for 85% of Q2 cell processing revenue, with the top 20 customers contributing 80% of BPM revenue. BioLife's BPM products are embedded in 16 approved therapies and used in over 250 commercially sponsored clinical trials in the U.S. The company also highlighted its strategic investment in Pluristyx and its efforts to cross-sell additional products to existing BPM customers. Despite broader macro uncertainties, BioLife remains optimistic about delivering sustainable growth through 2025 and beyond.

Strong Revenue Growth

BioLife Solutions reported Q2 revenue of $25.4 million, representing an increase of 29% year-over-year, primarily driven by a 28% increase in cell processing platform revenue.

Increased Revenue Guidance

The company raised its full year 2025 revenue guidance to $100 million to $103 million, reflecting an overall growth of 22% to 25%.

Cell Processing Revenue Surge

Cell processing revenue reached $23 million, a 28% year-over-year increase and up 6% sequentially, marking the seventh consecutive quarter of growth.

Adjusted EBITDA Margin Expansion

Adjusted EBITDA for Q2 2025 was $6.1 million or 24% of revenue, compared with $3.9 million or 20% of revenue in the prior year.

Strategic Investment in Pluristyx

BioLife made a strategic investment in Pluristyx, an early-stage developer of iPSC-based products, aligning with their interest in exploring biological assays.

Strong Cash Position

BioLife ended Q2 2025 with over $100 million in cash and marketable securities, enabling continued investment in strategic priorities.

BioLife Solutions (BLFS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BLFS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.01 / -	-0.04	―	―	―
Aug 07, 2025	2025 (Q2)	-0.03 / -0.33	-0.16	-106.25% (-0.17)	―
May 08, 2025	2025 (Q1)	-0.05 / -0.01	-0.22	95.45% (+0.21)	―
Mar 03, 2025	2024 (Q4)	-0.06 / -0.04	-0.3	86.67% (+0.26)	―
Nov 12, 2024	2024 (Q3)	-0.08 / -0.04	-0.67	94.03% (+0.63)	―
Aug 08, 2024	2024 (Q2)	-0.14 / -0.16	-0.23	30.43% (+0.07)	―
May 09, 2024	2024 (Q1)	-0.31 / -0.22	-0.32	31.25% (+0.10)	―
Feb 29, 2024	2023 (Q4)	-0.34 / -0.30	-1.15	73.91% (+0.85)	―
Nov 09, 2023	2023 (Q3)	-0.38 / -0.67	-0.23	-191.30% (-0.44)	―
Aug 08, 2023	2023 (Q2)	-0.21 / -0.23	-1.71	86.55% (+1.48)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BLFS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$20.64	$22.68	+9.88%
May 08, 2025	$22.36	$23.29	+4.16%
Mar 03, 2025	$24.00	$24.51	+2.13%
Nov 12, 2024	$26.50	$24.11	-9.02%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioLife Solutions (BLFS) report earnings?

BioLife Solutions (BLFS) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is BioLife Solutions (BLFS) earnings time?

BioLife Solutions (BLFS) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BLFS EPS forecast?

BLFS EPS forecast for the fiscal quarter 2025 (Q3) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing